Discusses the treatment of patients with metastatic melanoma by using autologous tumor-infiltrating lymphocytes (TIL) and interleukin 2. Results of using autologous TIL plus bolus interleukin 2 with or without the concomitant administration of cyclophosphamide; Objective responses of patients; Treatment's side effects; Value of immune lymphocytes.